Brought to you by 
Adlai Nortye licenses shelved Novartis compound buparlisib to develop combo cancer therapies
25 Oct 2021
Executive Summary
Adlai Nortye licensed exclusive worldwide development and commercialization rights to Novartis Pharma AG's buparlisib (BKM120) for all therapeutic, prophylactic, or diagnostic uses, except for certain rights Novartis retains.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adlai Nortye licenses shelved Novartis compound buparlisib to develop combo cancer therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice